Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: GEM-92, Hybridon Inc.

R Zheng1

  • 1Department of Immunology, St Bartholomew's Hospital, London, UK. r.q.zheng@mds.qmw.ac.uk

Current Opinion in Molecular Therapeutics
|November 21, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Punishments Enhance Reward Learning by Modulating Striatal Prediction Errors.

The Journal of neuroscience : the official journal of the Society for Neuroscience·2026
Same author

The Ontogeny of Mouse Salivary Gland Macrophages Is Distinct between Sexes.

Journal of dental research·2026
Same author

[Repair of postoperative defects following orbital tumors resection using 3D-printed preformed titanium meshes: a multicenter long-term retrospective study].

Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery·2025
Same author

[Research progress in diabetic lumbosacral radiculoplexus neuropathy].

Zhonghua nei ke za zhi·2025
Same author

[Knowledge, attitude and practice of salt reduction and hypertension status and related factors among restaurant practitioners in Beijing City].

Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]·2025
Same author

Safety, Pharmacokinetics, and Acceptability of a Tenofovir Rectal Microbicide Douche Among Young Men Who Have Sex With Men: The DREAM ATN Study (ATN 163).

The Journal of infectious diseases·2025
Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011
Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010
Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010
Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010
Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010
Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010
See all related articles

GEM-92, an oral antisense oligonucleotide, shows promise for treating HIV-1 infection by inhibiting viral replication. This next-generation compound is more stable than its predecessor and is currently in Phase I trials.

Area of Science:

  • Biotechnology
  • Antisense Oligonucleotide Therapeutics
  • Virology

Background:

  • Human Immunodeficiency Virus (HIV-1) infection and Acquired Immunodeficiency Syndrome (AIDS) remain significant global health challenges.
  • Antisense oligonucleotide (ASO) therapy offers a targeted approach to inhibit viral replication by interfering with viral gene expression.
  • GEM-91, an earlier ASO, showed potential but was discontinued due to dose-limiting toxicities.

Purpose of the Study:

  • To evaluate the safety, tolerability, and pharmacokinetic profile of GEM-92, a novel orally administered ASO targeting HIV-1 gag mRNA.
  • To compare the oral and intravenous administration of GEM-92 in healthy volunteers.
  • To assess the efficacy of GEM-92 in inhibiting HIV-1 replication in preclinical models.

Main Methods:

Related Experiment Videos

  • Phase I clinical trial in healthy volunteers to assess safety and pharmacokinetics.
  • Administration of single oral and intravenous doses of GEM-92 at escalating dose levels.
  • In vitro studies using cell culture systems to evaluate inhibition of HIV-1 replication and compound stability.

Main Results:

  • GEM-92 demonstrated significant inhibition of HIV-1 replication in various cell culture systems.
  • GEM-92 exhibited increased stability compared to its predecessor, GEM-91.
  • Phase I trials are underway to determine safety and pharmacokinetic profiles of oral and IV administration.

Conclusions:

  • GEM-92 represents a second-generation, orally administered ASO with potential as a novel therapeutic agent for HIV-1 infection.
  • The compound shows improved stability and significant antiviral activity in preclinical studies.
  • Ongoing clinical trials will further elucidate its therapeutic potential and safety profile.